MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
0.7007
-0.0283 (-3.88%)
At close: May 12, 2025, 4:00 PM
0.7108
+0.0101 (1.44%)
After-hours: May 12, 2025, 7:59 PM EDT
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$3,065,778
Market Cap
6.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MTVA News
- 3 days ago - MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - PRNewsWire
- 5 days ago - MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PRNewsWire
- 19 days ago - MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PRNewsWire
- 20 days ago - MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - PRNewsWire
- 27 days ago - MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability - PRNewsWire
- 7 weeks ago - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference - PRNewsWire
- 6 months ago - NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases - PRNewsWire